Related Experiment Video
Updated: Feb 8, 2026

Murine Surgical Model of Topical Elastase Induced Descending Thoracic Aortic Aneurysm
Published on: August 24, 2019
Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic Aneurysm
Mengcheng Shen1,2, Mei Hu1,2, Paul W M Fedak3,4
1From the Department of Physiology (M.S., M.H., Z.K.).
Rationale:
ADAM17 (a disintegrin and metalloproteinase-17) is a membrane-bound enzyme that regulates bioavailability of multiple transmembrane proteins by proteolytic processing. ADAM17 has been linked to several pathologies, but its role in thoracic aortic aneurysm (TAA) has not been determined.
Objective:
The objective of this study was to explore the cell-specific functions of vascular ADAM17 in the pathogenesis and progression of TAA.
Methods And Results:
In aneurysmal thoracic aorta from patients, ADAM17 was increased in tunica media and intima. To determine the function of ADAM17 in the major cells types within these regions, we generated mice lacking ADAM17 in smooth muscle cells (SMC; Adam17/Sm22 ) or endothelial cells (Adam17/Tie2 ). ADAM17 deficiency in either cell type was sufficient to suppress TAA dilation markedly and adverse remodeling in males and females (in vivo) although through different mechanisms. ADAM17 deficiency in SMCs prevented the contractile-to-synthetic phenotypic switching in these cells after TAA induction, preventing perivascular fibrosis, inflammation, and adverse aortic remodeling. Loss of ADAM17 in endothelial cells protected the integrity of the intimal barrier by preserving the adherens junction (vascular endothelial-cadherin) and tight junctions (junctional adhesion molecule-A and claudin). In vitro studies on primary mouse thoracic SMCs and human primary aortic SMCs and endothelial cells (±ADAM17 small interfering RNA) confirmed the cell-specific functions of ADAM17 and demonstrated the cross-species validity of these findings. To determine the impact of ADAM17 inhibition in treating TAA, we used an ADAM17-selective inhibitor (PF-548) before or 3 days after TAA induction. In both cases, ADAM17 inhibition prevented progression of aneurysmal growth.
Conclusions:
We have identified distinct cell-specific functions of ADAM17 in TAA progression, promoting pathological remodeling of SMC and impairing integrity of the intimal endothelial cell barrier. The dual impact of ADAM17 deficiency (or inhibition) in protecting 2 major cell types in the aortic wall highlights the unique position of this proteinase as a critical treatment target for TAA.
Insights
A disintegrin and metalloproteinase-17 (ADAM17) plays a key role in thoracic aortic aneurysm (TAA) progression by affecting smooth muscle cells and endothelial cells. Inhibiting ADAM17 shows promise for treating TAA.
Area of Science:
- Cardiovascular Biology
- Protease Function
- Aortic Disease Research
Background:
- ADAM17 (a disintegrin and metalloproteinase-17) is a membrane-bound enzyme involved in proteolytic processing of transmembrane proteins.
- ADAM17 is implicated in various pathologies, but its specific role in thoracic aortic aneurysm (TAA) pathogenesis was previously undetermined.
Purpose of the Study:
- To investigate the cell-specific roles of vascular ADAM17 in the development and progression of TAA.
- To determine if targeting ADAM17 could be a therapeutic strategy for TAA.
Main Methods:
- Analysis of ADAM17 expression in human aneurysmal thoracic aorta.
- Generation of mice with ADAM17 deficiency in smooth muscle cells (SMCs) or endothelial cells (ECs) to assess TAA progression in vivo.
- In vitro studies using primary mouse and human SMCs and ECs to confirm cell-specific functions.
- Administration of an ADAM17-selective inhibitor (PF-548) to evaluate therapeutic potential.
Main Results:
- ADAM17 expression was elevated in the tunica media and intima of human aneurysmal aortas.
- ADAM17 deficiency in either SMCs or ECs significantly suppressed TAA dilation and adverse remodeling in mice.
- Loss of ADAM17 in SMCs prevented phenotypic switching and fibrosis, while loss in ECs preserved the intimal barrier integrity.
- Inhibition of ADAM17, either before or after TAA induction, effectively prevented aneurysmal growth progression.
Conclusions:
- ADAM17 exhibits distinct cell-specific functions in TAA, promoting pathological SMC remodeling and compromising EC barrier integrity.
- Targeting ADAM17 in both SMCs and ECs offers a dual protective mechanism against TAA progression.
- ADAM17 is a critical therapeutic target for TAA due to its significant impact on key cell types within the aortic wall.
Related Concept Videos
Testosterone: Functions and Regulation
Cell Specific Gene Expression
Positive Regulator Molecules
Thoracic Aorta
pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...

